Literature DB >> 9428118

Donor left ventricular hypertrophy increases risk for early graft failure.

S Aziz1, L A Soine, S L Lewis, A P Kruse, W C Levy, K M Wehe, D P Fishbien, M D Allen.   

Abstract

A review of factors contributing to early mortality after cardiac transplantation revealed that up to 25% of deaths were due to primary graft dysfunction unrelated to rejection or infection. In light of this finding, evaluation of a donor heart with regard to its suitability for transplantation takes on added importance. In an effort to screen the suitability of donor hearts in the region covered by the Northwest Organ Procurement Agency (USA), all donors are evaluated by two-dimensional transthoracic echocardiography as part of the initial evaluation. A total of 110 donor echocardiograms were reviewed and an attempt was made to correlate the 30-day outcome with the parameters measured. An unexpected finding was that the presence of left ventricular hypertrophy in the donor heart was associated with an increase in the incidence of donor heart dysfunction compared with donors with normal echocardiographic profiles (33% vs 3%, P = 0.007).

Entities:  

Mesh:

Year:  1997        PMID: 9428118     DOI: 10.1007/s001470050084

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  3 in total

1.  Impact of donor left ventricular hypertrophy on survival after heart transplant.

Authors:  O Wever Pinzon; G Stoddard; S G Drakos; E M Gilbert; J N Nativi; D Budge; F Bader; R Alharethi; B Reid; C H Selzman; M D Everitt; A G Kfoury; J Stehlik
Journal:  Am J Transplant       Date:  2011-09-11       Impact factor: 8.086

2.  Donor predictors of allograft use and recipient outcomes after heart transplantation.

Authors:  Kiran K Khush; Rebecca Menza; John Nguyen; Jonathan G Zaroff; Benjamin A Goldstein
Journal:  Circ Heart Fail       Date:  2013-02-07       Impact factor: 8.790

Review 3.  Primary graft dysfunction after heart transplantation: a thorn amongst the roses.

Authors:  Sanjeet Singh Avtaar Singh; Jonathan R Dalzell; Colin Berry; Nawwar Al-Attar
Journal:  Heart Fail Rev       Date:  2019-09       Impact factor: 4.214

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.